Topic: Alzheimer's disease

This Keystone Symposium integrates fundamental mechanisms, precision diagnostics, and therapeutic development for Alzheimer's disease, non-Alzheimer dementias, and other neurodegenerative disorders. Joint programming with the Neural-Immune Interactions meeting connects disease mechanisms and clinical strategy with immune modulation of central nervous system biology.

Navigation and memory require coordination between map-like allocentric representations and body-centered egocentric actions. Aaron Wilber examines how the parietal–retrosplenial–anterior thalamic–hippocampal network performs these transformations, and how disrupted coordination contributes to spatial deficits in aging and Alzheimer’s disease. Rat sequence-task experiments reveal bidirectional hippocampal–parietal interactions across route-centered, place and egocentric representations. Because that task does not isolate reference-frame use, the laboratory developed a freely available task se

The Allen Institute has launched a new moonshot initiative on human brain health and disease called the Brain Health accelerator. This initiative aims to dramatically accelerate our understanding of human brain structure and function, identify the molecular, cellular and circuit basis of disease progression, and pioneer new therapeutic strategies targeting vulnerable and affected cell types. Our mission focuses on taking a human-centric approach to understanding and treating disease, combining a large-scale open science discovery approach across multiple diseases, AI-based disease modeling, an

The MIT Aging Brain Initiative brings together work in molecular imaging, cognition, chemistry, bioengineering, neurodegeneration, and artificial intelligence to address brain aging and Alzheimer's prevention.

Develop antibody-based approaches to Alzheimer’s disease at the Queensland Brain Institute. The project investigates tau-targeting monoclonal antibodies through protein production, cell-based experiments and mouse studies. Responsibilities include analysing results, preparing publications, contributing to funding applications and supporting junior researchers. This full-time appointment runs for up to 12 months, with an immediate start preferred. Annual base pay is AUD 85,373–113,660, plus 17% superannuation.

Bryce Mander presents research on early sleep biomarkers associated with Alzheimer's disease pathophysiology and memory impairment. The William C. Dement Seminar connects sleep and circadian neuroscience with neurodegeneration, cognition and clinically relevant approaches to detecting disease-related change.

Parallel Squared Technology Institute is recruiting research associate and senior research associate candidates to operate and maintain mass spectrometers, prepare protein samples, manage reagents and samples, and analyze experimental data. The institute is developing high-throughput protein-analysis technology with initial applications in Alzheimer’s disease and aging.

Ai2 is recruiting a postdoctoral Young Investigator for CellOLMo, a collaboration using open language models with single-cell brain data. The researcher will develop multimodal models that combine gene-expression data and text, evaluate biological language grounding on the SEA-AD Alzheimer's disease atlas, build donor- and brain-region-level representations, and release resulting models, code, data, and research artifacts openly.

Parallel Squared Technology Institute is recruiting scientist and senior-scientist candidates to use single-cell proteomics to investigate protein dysfunction in Alzheimer's disease and related neurodegenerative conditions. The work spans human brain tissue, molecular mechanisms, single-cell analysis, and computational biology in an interdisciplinary team.